Nancy Reau to Antiviral Agents
This is a "connection" page, showing publications Nancy Reau has written about Antiviral Agents.
Connection Strength
8.037
-
Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70.
Score: 0.556
-
Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
Score: 0.531
-
Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
Score: 0.501
-
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
Score: 0.493
-
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
Score: 0.480
-
Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
Score: 0.472
-
Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
Score: 0.426
-
Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305.
Score: 0.393
-
Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95.
Score: 0.356
-
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
Score: 0.343
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
Score: 0.339
-
Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71.
Score: 0.310
-
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
Score: 0.289
-
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
Score: 0.181
-
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
Score: 0.170
-
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
Score: 0.169
-
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
Score: 0.165
-
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593.
Score: 0.159
-
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
Score: 0.158
-
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
Score: 0.157
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
Score: 0.153
-
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
Score: 0.145
-
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
Score: 0.140
-
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
Score: 0.138
-
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
Score: 0.133
-
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
Score: 0.132
-
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
Score: 0.126
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.120
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
Score: 0.116
-
Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91.
Score: 0.106
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
Score: 0.043
-
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
Score: 0.040